Core Insights - Tempus AI (TEM) is on track to achieve a significant milestone in its 10th year, projecting a full-year adjusted EBITDA of $5 million, which represents an improvement of approximately $110 million over 2024 [1] - The company narrowed its adjusted EBITDA loss by $27.8 million year over year to negative $16.2 million, indicating effective cost management [1][10] Revenue and Profitability - First-quarter revenues surged by 75.4% year over year, driven by an 89% increase in Genomics, a 31% rise in Oncology testing, and a $63.5 million contribution from Hereditary testing [2] - Gross profit increased at an even higher rate of 99.8% year over year, nearly doubling the growth rate from the previous quarter, supported by gross margin expansion in Genomics and Data and services [2] Competitive Landscape - Compared to older peers like Guardant Health and Myriad Genetics, which are still facing significant annual losses, Tempus is experiencing rapid growth and margin improvements, positioning itself for a promising shift to profitability [3] - Guardant Health reported an adjusted EBITDA loss of $58.5 million for Q1 2025, while Myriad Genetics posted an adjusted EBITDA near breakeven [4][5] Stock Performance - Year to date, Tempus AI shares have increased by 71.8%, significantly outperforming the industry average growth of 22.9% [8][10] - The stock trades at a forward 12-month sales multiple of 7.36X, which is lower than its median of 28.64X but above the industry average of 6.03X [9]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Tempus AI, Inc. regarding possible violations of federal securities laws and other unlawful business practices [1][2] Group 1: Investigation and Claims - The investigation by Bragar Eagel & Squire, P.C. is on behalf of Tempus stockholders [1] - Spruce Point Capital Management published a report raising concerns about Tempus, including aggressive accounting practices and the background of several board members with troubled companies [2] - Following the report, Tempus's stock price experienced a significant decline during intraday trading on May 28, 2025 [2] Group 2: Company Background - Tempus AI, Inc. is publicly traded on NASDAQ under the ticker symbol TEM [2] - Bragar Eagel & Squire, P.C. is a law firm that represents individual and institutional investors in various types of litigation [4]

Core Viewpoint - Tempus AI's stock experienced a significant increase of 15% following positive announcements related to its AI-driven programs, despite facing allegations from short sellers regarding its AI usage [1][2]. Company Developments - Tempus, a precision medicine company utilizing AI, was recently targeted by a short report questioning its AI claims. In response, the company made announcements about two AI initiatives over the weekend, which seemed to mitigate concerns raised by the short seller [2]. - The company updated its AI platform, Tempus One, to include direct access to electronic health records (EHR) systems, enhancing its ability to gather real-time clinical, molecular, and imaging data from millions of patients [3]. - Tempus introduced an initiative called Fuses, aimed at creating an AI-enabled diagnostic platform that offers a comprehensive suite of algorithmic tests to advance precision medicine [5]. Market Reaction - Following the announcements, Tempus AI's stock surged, aligning with a broader market increase in the S&P 500 and Nasdaq Composite [1]. - TD Cowen maintained a buy rating for Tempus, indicating confidence in the company's prospects despite the short seller's allegations [5].

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Tempus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 28, 2025, S ...

Company Overview - Tempus AI, Inc. is a health technology company focused on developing AI-driven diagnostic tools for healthcare providers and researchers [3] Allegations and Impact - On May 28, 2025, Spruce Point Capital Management published a report raising concerns about Tempus AI's financial reporting methods and the involvement of its board members and executives with companies that had previously restated their financial results [4] - Following the report, Tempus AI's stock price fell by $12.67 per share, representing a decline of 19.23%, closing at $53.20 per share on the same day [4] Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws related to Tempus AI, stemming from allegations of misleading business information provided to the investing public [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tempus AI, Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Investigation and Legal Action - Shareholders of Tempus AI may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2] - The investigation follows a significant drop in Tempus AI's stock price, which fell by 19.2% on May 28, 2025, after a short-seller report raised concerns about the company's product integrity, management credibility, and financial reporting practices [3] Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [4] - The firm has been recognized for its performance in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking in the top 4 for settlements since 2013 [4]

In this video, I will talk about Tempus AI (TEM 3.12%) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of May 28, 2025. The video was published on May 29, 2025. ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Tempus investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley ...

Editor’s note: This story has been updated to include a statement from a Tempus AI spokesperson.Spruce Point Capital Management has announced a new short position against Tempus AI Inc. TEM. On Wednesday, the short seller raised concerns about the company’s management team.What To Know: Tempus AI shares are tumbling Wednesday morning. Shortseller Spruce Point targeted the Chicago-based company in a new report titled “The Tempest Surrounding Tempus AI.”The firm blasted Tempus AI founder and CEO Eric Lefkofsk ...